Rafael Holdings, Inc. (NYSE: RFL)

Rafael Holdings, Inc. (RFL) is a company that operates in the healthcare and real estate industries. Its main business activities include investments in clinical and early-stage pharmaceutical companies, development of medical devices, and ownership of real estate assets.

The company's pharmaceutical segment includes Cornerstone Pharmaceuticals, Inc., a clinical stage cancer metabolism-based therapeutics company, and LipoMedix Pharmaceuticals Ltd., a clinical stage Israeli company that develops a product candidate, Promitil. Cornerstone Pharmaceuticals focuses on the development of CPI-613, a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is designed to disrupt mitochondrial function and thereby decrease the TCA cycle function in cancer cells. LipoMedix Pharmaceuticals, on the other hand, develops Promitil, a pegylated liposomal mitomycin-C lipidic prodrug, which aims to overcome the toxicity associated with the clinical use of mitomycin-C and turn it into a targeted, anticancer therapeutic.

In the medical devices segment, Rafael Holdings has an investment in Rafael Medical Devices, LLC, an orthopedic-focused medical device company that develops instruments to advance minimally invasive surgeries. The company has raised $925,000 from third parties and maintains approximately 53% of Rafael Medical Devices on a fully diluted basis.

Rafael Holdings' real estate asset is a portion of a commercial building in Jerusalem, Israel.

The company's competitive advantage lies in its strong portfolio of pharmaceutical companies, which have developed innovative products with potential to address unmet medical needs. Cornerstone Pharmaceuticals and LipoMedix Pharmaceuticals have both completed several clinical trials for their respective product candidates, demonstrating promising results in terms of safety, tolerability, and efficacy.

Rafael Holdings' customers include patients with various types of cancers, including pancreatic cancer, breast cancer, and ovarian cancer, as well as patients with Niemann-Pick Type C disease. The company's products are designed to address the unmet medical needs of these patients.

Rafael Holdings, Inc. has a diverse portfolio of pharmaceutical companies, medical devices, and real estate assets. The company's primary focus is to expand its investment portfolio through opportunistic and strategic investments, including therapeutics that address high unmet medical needs. Its competitive advantages include its strong portfolio of pharmaceutical companies and its ability to identify and invest in promising early-stage companies with innovative products.

The brand names and/or trade names of its products and services include CPI-613 from Cornerstone Pharmaceuticals, Inc. and Promitil from LipoMedix Pharmaceuticals Ltd.